Pappas Capital Announces the Passing of…

Dynogen Pharmaceuticals, Inc. announced today the presentation of positive results from its Phase 2a trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d) at the Digestive Disease Week 2008 (DDW) scientific meeting. The randomized, double-blind, placebo controlled trial established clinical proof-of-concept with statistically significant results for the endpoint of relief of abdominal pain or discomfort associated with IBS-d. Dynogen previously reported top-line results from this Phase 2a trial in December 2007. The DDW abstract was co-authored by Dynogen and a team of investigators from leading clinical centers in Canada. The DDP225 results were presented yesterday in a Distinguished Abstract Plenary session on Neurogastroenterology and Motility by Steven B. Landau, M.D., a member of Dynogen’s Scientific Advisory Board.

Apex Bioventures Acquisition Corp. (AMEX: PEX), a publicly traded special purpose acquisition company with healthcare industry expertise, and
Dynogen Pharmaceuticals, Inc., a privately owned clinical stage biopharmaceutical company focused on gastrointestinal and genitourinary disorders, announced today the signing of a definitive merger agreement.

Dynogen Pharmaceuticals, Inc. today announced that the Company has acquired from Arachnova Therapeutics, Ltd. all of its worldwide patent rights and know- how related to DDP225 in an asset purchase agreement. The Arachnova patent rights, which include granted patents and pending applications related to the use of DDP225 for the treatment of functional bowel disorders, genitourinary (GU) disorders and pain, complement and enhance Dynogen’s existing extensive worldwide patent estate related to DDP225. Financial terms of the agreement were not disclosed.

Dynogen Pharmaceuticals, Inc. today announced positive results from its Phase 2 trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d). The randomized, double-blind, placebo controlled trial generated statistically significant results for the clinical endpoint of relief from abdominal pain or discomfort associated with IBS-d. Detailed results will be submitted for disclosure in a peer-reviewed journal or at a future medical conference.

Dynogen Pharmaceuticals, Inc. announced today that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c). This DDP733 Phase 2b trial is a randomized, double-blind, placebo controlled study that is enrolling female patients with IBS-c at multiple centers in the U.S. and Canada. The study is assessing efficacy using the Overall Subject Global Assessment (OSGA) of relief of IBS symptoms, as well as the safety and tolerability of the drug.

Dynogen Pharmaceuticals, Inc. announced the presentation of its positive Phase 1b trial results for its DDP733 (pumosetrag) nocturnal gastroesophageal reflux disease (NGERD) program at the American College of Gastroenterology Annual Scientific Meeting (ACG) in Philadelphia, PA. The randomized, double-blind, placebo-controlled study demonstrated proof-of- concept and overall safety and tolerability of DDP733 in reducing reflux events. The ACG abstract was authored by researchers from the Mayo Clinic and Dynogen. The DDP733 results were presented on October 14, 2007 during a poster session.

Dynogen Pharmaceuticals, Inc. today reported positive results of its randomized, double-blind, placebo–controlled, parallel group Phase 2 trial of DDP733 in patients with irritable bowel syndrome with constipation (IBS-c). DDP733 achieved an overall clinical response rate of 54% in patients receiving a dose of 1.4 mg t.i.d. compared to a 15% clinical response rate for patients receiving placebo. This was a statistically significant difference in a clinical endpoint which has been accepted by the FDA as a registration endpoint for this indication. The drug was well tolerated in this study. Detailed results will be submitted for disclosure in a peer-reviewed journal or at a future medical conference.